Item 8.01 - Other Events: Ventas, Inc. entered into Amendment No. 2 to its ATM (At-The-Market) Sales Agreement on February 9, 2026, modifying the original agreement dated September 18, 2024 and Amendment No. 1 dated June 13, 2025 Multiple Underwriters: The amendment involves a syndicate of investment banks including BofA Securities, BBVA Securities, BNP Paribas Securities, BNY Mellon Capital…

Our analysis rates this filing NEUTRAL. This 8-K filing represents routine capital markets activity for a large healthcare REIT managing its capital structure. The primary concern is equity dilution from the $2.5B ATM program expansion, which is material in magnitude but standard practice for REITs…

Concern level: MODERATE (3.8/10). Key factors: Equity dilution risk from $2.5B ATM program expansion - material shareholder dilution potential if fully deployed; Defensive management tone with extensive risk factor disclosures - typical for ATM filings but reflects cautious posture; No financial guidance or operational metrics provided - limits visibility into current business performance.

Notable risk changes: ATM Sales Agreement expanded: Amendment No. 2 increases authorized common stock issuance capacity to $2.5B (excludes previously sold shares), adding M&T Securities as additional sales agent. This represents material increase in equity dilution capacity.; No material negative events disclosed: This is a routine ATM program amendment with no indication of covenant breaches, liquidity concerns,…

The model predicts VTR will underperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.